Work

Long-term follow-up and late complications of CAR-T cell therapy

Year: 2026
Type: article
Abstract: Background: Chimeric antigen receptor T-cell (CAR-T cell) therapy has transformed the treatment landscape for relapsed or refractory hematologic malignancies. As the number of long-term survivors continues to grow, the recognition and management of late complications have become critical clinical priorities. The existing literature remains fragmented, with limited long-term prospective data and a lack of unified follow-up guidelines. Methods: A narrative review of the literature was conducted using PubMed, MEDLINE, and Google Scholar databases from inception through April 2026. Key search terms included long-term follow-up, survivorship, late effects, CAR-T cell therapy, chimeric antigen receptor, late complications, delayed cytopenias, hypogammaglobulinemia, secondary malignancies, immune reconstitution, and screening. This review synthesizes available evidence with expert consensus recommendations. Results: The review identifies prolonged cytopenias, hypogammaglobulinemia and infectious complications as the most prevalent late effects. Secondary myeloid neoplasms occur with a shorter latency than historically observed after conventional chemotherapy. Neurocognitive deficits following immune effector cell-associated neurotoxicity syndrome generally resolve within six months. Cardiovascular, endocrine, and reproductive late effects are emerging areas of concern with limited specific data. Conclusion: Structured, long-term, multidisciplinary follow-up is essential for CAR-T cell therapy recipients. This review provides recommendations for the long-term surveillance and management of these patients. Prospective registries and standardized screening protocols are urgently needed.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7237218577
FWCI:
Cites: 71
Cited by:
Related to: 10